Latest News
Acumen Pharmaceuticals phase 2 Alzheimer's trial misses primary endpoint
30 October 2026 - Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company based in Newton, Massachusetts, on Friday said that initial topline results from its Phase 2 ALTITUDE-AD trial showed sabirnetug (ACU193) failed...
Immunome secures EMA validation of varegacestat application for desmoid tumors
30 October 2026 - Biotechnology company Immunome Inc (Nasdaq:IMNM) announced on Friday that the European Medicines Agency (EMA) has validated its Marketing Authorization Application for varegacestat, an investigational oral, once-daily gamma secretas...
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
30 October 2026 - India-based pharmaceutical company Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) said on Friday that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for ILUMY...
Alkermes initiates phase 2 study of ALKS 7290 for major depressive disorder
30 October 2026 - Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) announced on Friday that it has initiated a phase 2 clinical study evaluating ALKS 7290 as an adjunctive treatment for adults with major depressive disorder (MDD), expanding the d...
Perrigo to pay quarterly dividend of USD0.29 per share
30 October 2026 - Perrigo Company plc (NYSE: PRGO), a provider of consumer self-care products, announced on Thursday that its board of directors has approved a quarterly cash dividend of USD0.29 per share, or USD1.16 per share on an annualised basis....